On Sunday at the AUA conference there was a poster (#159) titled ADJUVANT VS. SALVAGE RADIATION THERAPY FOLLOWING PROSTATECTOMY FOR LOCALLY ADVANCED PROSTATE CANCER: RESULTS FROM SEER-MEDICARE written by Keith J. Kowalczyk, etal. The researchers evaluated the optimal timing of external beam radiation (RT) after the completion of a radical prostatectomy (RP) as primary treatment [...]
Currently the American Urologic Association is holding their annual conference. Like the ASCO and AACR conferences there are many presentations and posters given that harkens the latest in research findings for general urological topics as well as for prostate cancer. I will be reporting on a number of these findings over the next period of [...]
You are sitting in your doctor’s office listening to the doctor tell you that you have prostate cancer! Immediately, numbness and disbelief creep into your reality. Over time, the news sinks in and you begin to understand the diagnosis, you have cancer. Your world has been changed and will never be the same. All of [...]
Sometimes I have heard the question, Where can prostate cancer metastasis (met) be found? Usually, the question really means, how can my met in my spleen or liver (or what ever) come from my prostate cancer? In realty, prostate cancer tumors can develop anywhere in the human body! There was a study of human cadavers [...]
For our European readers who have not yet started, but are getting ready to start hormone deprivation therapy (ADT), there is a new clinical trial you should consider. This trial is evaluating MDV3100 monotherapy as the first hormonal treatment of patients with prostate cancer. Enrolled men would not have had any previous hormonal therapies for [...]
Five years ago today I started this little blog. A lot has happened to me over the years since and many lessons have been learned. I can honestly say that I am a different person in the sense that I have grown up quite a bit, but I am still me. I can be no [...]
Over the last year or so we have seen a marked change in the treatment landscape for men with castrate resistant advanced prostate cancer. The FDA has approved sipuleucel-T (Provenge), cabazitaxel (Jevtana) and last week it also approved abiraterone (Zytiga). This changed landscape of multiple treatment options creates new problems, of course good problems. Prostate [...]
Federal research funding for prostate cancer accounts for around $400 million per year. The Prostate Cancer Research Program at the Department of Defense has received about $80 million per year since 2001. Funding at the PCRP has accelerated the clinical trial process for several drugs over the past couple of years including the recently approved [...]
Recall: Coumadin (warfarin sodium) Crystalline 5 mg Tablets - Tablets May Have Higher than Expected Potency ISSUE: Bristol-Myers Squibb initiated a voluntary recall of one lot of 1,000-count bottles of Coumadin (warfarin sodium) Crystalline 5 mg tablets. Company testing of tablets from a returned bottle found a tablet to be higher in potency than expected. [...]
We often talk about the assumed fact that androgen deprivation therapy (ADT) changes both the blood glucose levels as well as cholesterol levels in men who are under treatment. Researchers at the Division of General Internal Medicine & Clinical Epidemiology, University Health Network, University of Toronto, Toronto, ON. decided to formally evaluate this theory over [...]
